Bifogade filer
PDF
Kurs
-0,32%
Likviditet
2,57 MSEK
Kalender
| Est. tid* | ||
| 2025-10-23 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | N/A | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2025-05-06 | N/A | Årsstämma |
| 2025-04-29 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-08-01 | - | Extra Bolagsstämma 2024 |
| 2024-05-07 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2024-05-06 | - | Årsstämma |
| 2024-05-06 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-26 | - | Bokslutskommuniké 2023 |
| 2023-10-31 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-19 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-27 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-01 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-06 | - | Extra Bolagsstämma 2021 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2021-05-25 | - | Årsstämma |
| 2021-05-17 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-28 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Extra Bolagsstämma 2019 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning DICOT 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, March 26, 2025. The last day of trading in warrants TO 6 in Dicot Pharma is tomorrow, March 27, 2025. Warrant holders who cannot or do not intend to exercise their warrants are therefore encouraged to sell them no later than tomorrow so that other investors have the opportunity to exercise them. Tomorrow is therefore also the last day to buy more TO 6.
Buying and selling TO 6
Until tomorrow, March 27, it is possible to trade in "DICOT TO 6" through nominees such as Avanza, Nordnet, or other banks. Trading means that holders who cannot or do not intend to exercise the options for subscription can sell them, and that those who want more may buy. This option is only applicable in countries where so permitted.
Exercise TO 6
Holders of TO 6 can for each option subscribe for two new shares in Dicot Pharma for SEK 0.19 per share, which is 70% of the average price of the share February 24-March 10, 2025. This corresponds to a subscription price of SEK 0.38 per option. The exercise period for the warrants runs until Monday March 31, 2025, but note that some banks and nominees end subscription a day earlier. TO 6 that are not exercised expire worthless.
Holders who have their warrants nominee-registered at e.g., Avanza, Nordnet, or other bank report participation to their custodian.
Holders who have the warrants directly registered on a securities account (VP-konto) subscribe by simultaneous cash payment according to instructions on the application form available on www.dicotpharma.com.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.